HOME >> MEDICINE >> NEWS
RIT takes eye-tracking research to next level

How do we use our eyes to perceive the world? Could eye movements be windows into human cognition?

Scientist Jeff Pelz thinks so. The director of the Visual Perception Laboratory at Rochester Institute of Technology studies the link between eye movements and cognition. His latest research, in collaboration with the National Technical Institute for the Deaf (NTID), focuses on how deaf students process information in the classroom. Another project tracks how the human eye perceives high-speed motion on large-scale LCD monitors for Sharp Research Laboratory of America.

Until recently, visual perception research was rooted in laboratories where subjects looked at simple patterns on monitors in darkened rooms. Pelz argues that those experiments tell scientists little about how people use their eyes in daily life.

"The overarching question is how much of what we learn in the laboratory can we extend to the real world?" asks Pelz, an associate professor at RIT's Chester F. Carlson Center for Imaging Science.

The wearable eye tracker-new technology developed in the Visual Perception Laboratory-is helping to answer those questions. The eye tracker has transformed the field of visual perception by enabling subjects to wear the technology outside of the laboratory and even outdoors.

"The system we've developed at RIT is unique in its ability to automatically monitor even complex tasks in a large range of environments," Pelz says. "We can study students in a classroom or people finding their way in the woods."

The wearable eye tracker extends the laboratory to the real world by recording what people look at and how their eyes move as they perform a specified task, such as attending to a lecture in a classroom, driving a car, walking or playing racquetball. In other words, the device tracks how eye movements support perception and what people pay attention to in order to gather the information they need to perform everyday activities.


'"/>

Contact: Susan Gawlowicz
smguns@rit.edu
585-475-5061
Rochester Institute of Technology
23-Mar-2005


Page: 1 2 3

Related medicine news :

1. Male surgeons report highest rate of mistakes in patient care
2. Dairy, moderate fat, carbohydrate intakes reduce obesity in young teens
3. Sleep shortage takes toll on middle schoolers
4. UCSF physicians publish groundbreaking book on medical mistakes
5. Criminalising medical mistakes is questionable
6. Couch potato lifestyle takes a big bite out of health
7. OHSU takes part in unique Alzheimers treatment trial
8. Study adds to knowledge of what it takes to stand up, walk
9. Medical mistakes under the microscope
10. Devices that emit sounds to track medical status or pinpoint military targets may cause mistakes
11. Cognitive neuroscience takes on alcohol

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: RIT takes eye tracking research next level

(Date:6/17/2013)... According to a June 11, 2013 ABC News article, ... information surfaces about the negative effects of sun on ... one’s skin care routine, as the sun's rays ... , “I agree with the article's suggestions for the best ... of Epione Beverly Hills. “Apply a minimum of SPF 30, ...
(Date:6/17/2013)... Harvard Stem Cell Institute (HSCI) researchers have identified in ... to regulate embryonic stem cell self-renewal, beginning a creative ... , The gene, SALL4, gives stem cells their ability ... mature cells. Typically, cells only express SALL4 during embryonic ... cases of acute myeloid leukemia and 10 to 30 ...
(Date:6/17/2013)... childhood obesity, researchers at the Johns Hopkins Bloomberg ... are important. A systematic review of childhood obesity ... incorporate schools and focus on both diet and ... in children. The results of the study appear ... "In measuring the effectiveness of community-based programs that ...
(Date:6/17/2013)... pyrvinium pamoate inhibits aggressive forms of prostate cancer that ... conducted in an animal model. The results will be ... in San Francisco. , "Our novel prostate cancer drug ... lead author Jeremy Jones, PhD, assistant professor of molecular ... Duarte, CA. "Thus, it has the potential to treat ...
(Date:6/17/2013)... Reliable services of Link to Pay have been offered to ... can fix payment processing. , Schools and colleges have a ... fees from students and processing them may be a herculean ... cases, colleges and universities are looking for some smart solutions ... efficiently without any complications. , At the same time, parents ...
Breaking Medicine News(10 mins):Health News:Skin Care – Answers to Your Sunscreen Questions 2Health News:A new target for cancer drug development 2Health News:Community-based programs may help prevent childhood obesity 2Health News:New medication treats drug-resistant prostate cancer in the laboratory 2Health News:PayCanada Offers Link to Pay Services to its Customers 2
(Date:6/17/2013)... TORONTO , June 17, 2013  Generex ... it entered into a securities purchase agreement with certain ... agreed to purchase in a private placement an aggregate ... Series E 9% Convertible Preferred Stock ("convertible preferred stock") ... 100% of the shares of its common stock issuable ...
(Date:6/17/2013)... -- Franciscan St. Francis Health Cancer Center today ... Indiana to use a new drug to treat ... Xofigo ®, a radiopharmaceutical used in patients with late-stage, ... was approved for use by the U.S. Food and Drug ... it may become castration-resistant, which has become resistant to medical ...
(Date:6/17/2013)... OSAKA, Japan , June 17, 2013 ... Takeda Pharmaceuticals U.S.A. , Inc. today ... KAZANO (alogliptin and metformin HCl) and OSENI (alogliptin and ... the United States (U.S.). These ... Administration (FDA) for the treatment of type 2 diabetes ...
Breaking Medicine Technology:Generex Announces $1,225,000 Capital Investment 2Generex Announces $1,225,000 Capital Investment 3Generex Announces $1,225,000 Capital Investment 4Generex Announces $1,225,000 Capital Investment 5New drug proving effective in attacking advanced prostate cancer 2Takeda Type 2 Diabetes Therapies, NESINA (alogliptin) and Fixed-Dose Combinations KAZANO (alogliptin and metformin HCl) and OSENI (alogliptin and pioglitazone), Are Now Available in Pharmacies in the United States 2Takeda Type 2 Diabetes Therapies, NESINA (alogliptin) and Fixed-Dose Combinations KAZANO (alogliptin and metformin HCl) and OSENI (alogliptin and pioglitazone), Are Now Available in Pharmacies in the United States 3Takeda Type 2 Diabetes Therapies, NESINA (alogliptin) and Fixed-Dose Combinations KAZANO (alogliptin and metformin HCl) and OSENI (alogliptin and pioglitazone), Are Now Available in Pharmacies in the United States 4Takeda Type 2 Diabetes Therapies, NESINA (alogliptin) and Fixed-Dose Combinations KAZANO (alogliptin and metformin HCl) and OSENI (alogliptin and pioglitazone), Are Now Available in Pharmacies in the United States 5Takeda Type 2 Diabetes Therapies, NESINA (alogliptin) and Fixed-Dose Combinations KAZANO (alogliptin and metformin HCl) and OSENI (alogliptin and pioglitazone), Are Now Available in Pharmacies in the United States 6Takeda Type 2 Diabetes Therapies, NESINA (alogliptin) and Fixed-Dose Combinations KAZANO (alogliptin and metformin HCl) and OSENI (alogliptin and pioglitazone), Are Now Available in Pharmacies in the United States 7Takeda Type 2 Diabetes Therapies, NESINA (alogliptin) and Fixed-Dose Combinations KAZANO (alogliptin and metformin HCl) and OSENI (alogliptin and pioglitazone), Are Now Available in Pharmacies in the United States 8Takeda Type 2 Diabetes Therapies, NESINA (alogliptin) and Fixed-Dose Combinations KAZANO (alogliptin and metformin HCl) and OSENI (alogliptin and pioglitazone), Are Now Available in Pharmacies in the United States 9
Cached News: